Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRI6YT)

• Drug Name: BI 836880 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neoplasm	2A00-2F9Z	Phase 1	[1]
Wet age-related macular degeneration	9B78.3Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMRI6YT

Molecule-Related Drug Atlas

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[4]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[5]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[6]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[7]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[8]
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[9]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[10]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
REGN-910	DMHR7D4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Drug(s) Targeting Vascular endothelial growth factor (VEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[14]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[16]
M710	DM1PRT6	Diabetic macular edema	9B71.02	Phase 3	[17]
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[18]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[19]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[20]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[21]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[22]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Blocker	[3]
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Blocker	[3]

References

• [1] ClinicalTrials.gov (NCT03972150) A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03861234) A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [4] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [5] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [6] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [7] Company report (Roche pipeline: July 27, 2017)
• [8] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of CovX (2011).
• [12] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [13] Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
• [14] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [15] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [16] National Cancer Institute Drug Dictionary (drug id 43234).
• [17] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [18] Clinical pipeline report, company report or official report of Fujifilm.
• [19] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [20] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [21] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [22] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
• [23] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.